Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Top 50 ETF (Symbol: XLG) where we have detected an ...

Eli Lilly broadened its cancer research efforts in 2019 when it purchased Loxo Oncology for $8 billion. At the time, Eli Lilly CEO David Ricks told CNBC, ...

Eli Lilly (LLY 1.34%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade as it bets on multi-billion dollar markets for treating ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy gains steam in the obesity space. But Wall Street wiped out more ...

Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year. It has also upgraded its guidance.

Eli Lilly and Co., is acquiring a California-based biotech company that specializes in diabetes treatment research, the company announced Wednesday.

Eli Lilly’s stock surged on the encouraging data. It closed up by 14 percent on Thursday, adding $100 billion to the company’s market value. This was the first of seven main clinical trials of ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the ...